13856 research outputs found
Sort by
Association of frailty and chronic limb-threatening ischemia in patients on maintenance hemodialysis: A prospective cohort study
No full text[[abstract]]Chronic limb-threatening ischemia (CLTI) is a prevalent yet unpredictable complication among patients undergoing hemodialysis, and frailty is linked to adverse outcomes in this population. This study examined the influence of clinical factors on vascular events in patients undergoing hemodialysis. This multicenter prospective cohort study included patients undergoing maintenance hemodialysis since January 2008. The initial cohort consisted of 1,136 patients, 828 of whom successfully underwent a frailty test. CLTI events were recorded at 3-month intervals until December 31, 2022. The mean patient age was 67 years, and 48% were female. Overall, 34% of participants were frail, 38% pre-frail, and 28% not frail. Frailty phenotype was associated with age, female sex, low educational level, diabetes mellitus, and history of stroke. During a median follow-up of 1461 days, 104 patients experienced CLTI events (not frail, 6.5%; pre-frail, 11%; frail, 20%; P < 0.001). Frail patients had a higher risk of CLTI than those who were non-frail (hazard ratio (HR) 3.94; 95% confidence interval (CI) 2.22-6.99; P < 0.001). After multivariable adjustment for age and comorbidities, frailty remained significantly associated with CLTI (HR 3.26; 95% CI 1.76-5.85; P < 0.001). Conclusively, these findings highlight the risk of CLTI in frail patients undergoing hemodialysis
Myeloperoxidase and thyrotropin-releasing hormone within leukaemia stem cells increased chemosensitivity in acute myeloid leukaemia
No full text[[abstract]]Leukaemia stem cells (LSCs) are major contributors to chemoresistance in acute myeloid leukaemia (AML). Identifying potential biomarkers within LSCs that can predict chemosensitivity in AML is key. This prospective study involved 20 consecutive de novo AML patients who underwent ‘7 + 3’ induction therapy. The patients were divided into CR (n = 15) and non-CR (n = 5) groups. Using single-cell RNA sequencing, we examined the cellular states of bone marrow mononuclear cells from AML patients at diagnosis and identified LSC among these cells. Our results showed that in non-CR AML patients, a significant increase in the proportion of immature cells during haematopoiesis within the AML cell populations was observed. Moreover, the expression of myeloperoxidase (MPO) (log2 fold-change = 0.89; adjusted p < 0.0001) and thyrotropin-releasing hormone (TRH) (log2 fold-change = 0.65; adjusted p < 0.0001) was higher within LSCs in the CR group than in the non-CR group. Furthermore, patients with higher expression of MPO and TRH demonstrated improved relapse-free survival (p = 0.002 for MPO; p = 0.009 for TRH) and overall survival (p = 0.002 for MPO; p < 0.001 for TRH). The connection between MPO or TRH and chemosensitivity could be linked with the downregulation of transforming growth factor and the upregulation of interferon-α. In conclusion, MPO and TRH in LSCs could serve as chemosensitivity biomarkers in AML
Dual-function antibodies targeting VEGFR2 and VEGFR3
No full text[[abstract]]An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3)
단백질 키나아제 억제제로서의 아미노티아졸 화합물
No full text[[abstract]]하기에 나타낸 화학식 Ⅰ의 아미노티아졸 화합물 및 이러한 화합물 중 하나를 포함하는 약제학적 조성물: [화학식 Ⅰ] . 또한 아미노티아졸 화합물 중 하나를 이용하여 타이로신 키나아제를 억제하고 타이로신 키나아제와 관련된 암을 치료하는 방법이 기재되어 있다
融合タンパク質,核酸分子,宿主細胞,医薬組成物,及び医薬組成物の使用方法
No full text[[abstract]]A fusion protein, comprising: (i) a first vascular endothelial growth factor (VEGF) isoform, and (ii) a second VEGF isoform, and (iii) a dimerization domain between th
[[alternative]]Anti-obesity microbiota compositions and preparation methods and uses thereof
No full text[[abstract]]本發明係關於微生物叢組合物及其製備方法和用途。 具體而言，本發明提供從雙特異性磷酸酶6（dusp6）缺陷型哺乳動物收集的微生物叢組合物，其有效改變腸道微生物叢的相對豐度，並且還可用於降低體重、脂肪量及/或脂肪細胞大小，並且增加氧消耗和/或能量消耗，因此，可以用於在有需要的個體中治療或預防肥胖或其相關疾病或病症
[[alternative]]Focused ultrasound device for dermatological treatmen
No full text[[abstract]]本發明是一種治療皮膚的聚焦超音波裝置。本裝置包含一個聚焦超音波探頭、自動位移機構、驅動器、電腦以及軟體操作介面。皮膚治療方法為透過同一個聚焦超音波探頭實現同一個皮膚位置同軸向深與淺的消融治療
[[alternative]]A microfluidic hydrodynamic shuttling chip device for highthroughput multiple single cells capture
No full text[[abstract]]本發明揭露一種微流體動力式轉運晶片包含一單細胞捕捉單元陣列。每一單元包含：(a)一入口通道具有一捕捉處；(b)一大容室位於捕捉處的後方且具有一接收處其與捕捉處相距一距離g；(c)一侷限通道位於捕捉處以及接收處之間；(d)一容室通道可流通地位於大容室後方；以及(e)一迴避通道並列於入口通道、大容室以及容室通道且具有一第一端及一第二端相對第一端，其中第一端係由鄰近捕捉處前方的入口通道分支出，而第二端則接合於容室通道。本發明亦揭露捕捉多於一種單細胞的方法
Selective particles transfer from one device to another
No full text[[abstract]]A target particle transferring device is disclosed, which comprises: (a) a substrate with a thickness of T and a width of W, having top and bottom portions, the top portion having a top surface and the bottom portion having a bottom surface; (b) a notch structure formed in the bottom portion of the substrate, comprising: a groove with a width of W1, located at a distance oft below the top surface of the substrate, wherein the groove is formed in the bottom portion from the bottom surface extending toward the top portion; and (c) a target substrate portion with a width of W2 and a thickness of T, located in the top and bottom portions of the substrate and being surrounded by the groove. Methods of transferring a target particle from one device to another is also disclosed
Mesoporous silica nanoparticles for oil absorption
No full text[[abstract]]Compositions comprising an effective amount of mesoporous silica nanoparticles (MSNs) for use in prevention and/or treatment of steatorrhea in a subject in need thereof are disclosed. Also disclosed are compositions for use in exposing a liquid lipid to MSNs and causing the liquid lipid to gel and/or solidify, or compositions for use in exposing a liquid dietary lipid inside intestines of a subject to the MSNs and causing the liquid dietary lipid to gel and/or solidify inside the intestines of the subject, or compositions for use in reducing intestinal absorption of the liquid dietary lipid